| 前收市價 | 99.20 |
| 開市 | 99.80 |
| 買盤 | 101.20 x 21100 |
| 賣出價 | 101.30 x 8200 |
| 今日波幅 | 99.50 - 101.70 |
| 52 週波幅 | 81.35 - 122.90 |
| 成交量 | |
| 平均成交量 | 112,948 |
| 市值 | 3.471B |
| Beta 值 (5 年，每月) | 0.90 |
| 市盈率 (最近 12 個月) | 28.88 |
| 每股盈利 (最近 12 個月) | 3.48 |
| 業績公佈日 | 2024年7月11日 |
| 遠期股息及收益率 | 1.25 (1.24%) |
| 除息日 | 2024年6月06日 |
| 1 年預測目標價 | 89.60 |
- Reuters
UPDATE 4-Gerresheimer supplies the top two in weight-loss drugs, CEO says
German packaging and medical equipment maker Gerresheimer has contracts with the leading players in the burgeoning weight-loss drugs sector, CEO Dietmar Siemssen said after the company reported first-quarter earnings on Thursday. While Gerresheimer's first-quarter adjusted core profit rose 3.7% to 80.9 million euros ($86.9 million), the plastics and devices division that makes injector pens stole the show with a 26.5% jump to 59.3 million euros. Such drugs are expected to bring at least 350 million euros of annual revenue for Gerresheimer within three years, Siemssen said last month without naming specific customers.
ReutersWeight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors. Novo Nordisk's popular obesity drug Wegovy and Eli Lilly's in demand Zepbound are GLP-1 drugs. Siemssen said he expects sales related to GLP-1 medicines to surpass 100 million euros this year and to reach at least 350 million euros ($379 million) within the next three years, based on actual contracts and orders.
